Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Ann Oncol ; 24(8): 2108-12, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23585513

ABSTRACT

BACKGROUND: The role of [¹8F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) in follicular lymphoma (FL) staging is not yet determined. PATIENTS AND METHODS: The aim of the present study was to investigate the role of PET in the initial staging of FL patients enrolled in the FOLL05-phase-III trial that compared first-line regimens (R-CVP, R-CHOP and R-FM). Patients should have undergone conventional staging and have available PET baseline to be included. RESULTS: A total of 142 patients were analysed. PET identified a higher number of nodal areas in 32% (46 of 142) of patients and more extranodal (EN) sites than computed tomography (CT) scan. Also, the Follicular Lymphoma International Prognostic Index (FLIPI) score increased in 18% (26 of 142) and decreased in 6% (9 of 142) of patients. Overall, the impact of PET on modifying the stage was highest in patients with limited stage. Actually, 62% (15 of 24) of cases with limited disease were upstaged with PET. CONCLUSIONS: The inclusion of PET among staging procedures makes the evaluation of patients with FL more accurate and has the potential to modify therapy decision and prognosis in a moderate proportion of patients. Further prospective clinical trials on FL should incorporate PET at different moments, and the therapeutic criteria to start therapy should be re-visited in the views of this new tool.


Subject(s)
Fluorodeoxyglucose F18 , Lymphoma, Follicular/diagnostic imaging , Neoplasm Staging/methods , Positron-Emission Tomography , Tomography, X-Ray Computed , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Humans , Italy , Male , Middle Aged , Neoplasm Metastasis/diagnosis , Prednisone/therapeutic use , Prognosis , Radiopharmaceuticals , Retrospective Studies , Vincristine/therapeutic use
2.
Ann Oncol ; 17(7): 1146-51, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16687417

ABSTRACT

BACKGROUND: Conflicting results have been reported about the prognostic relevance of antecedent myelodysplastic syndrome (MDS) in acute myeloid leukemia (AML) of older adults. PATIENTS AND METHODS: Data from 87 intensively treated AML patients (median age 69 years) were analyzed, with the aim of comparing therapeutic results and toxicity between de novo and AML secondary to a previous MDS (s-AML). Rate of CD34+ cells mobilization and feasibility of autologous stem cell transplantation (ASCT) were also compared. RESULTS: Complete remission rate, death in induction and primary resistance were not statistically different between the two groups. Median time for neutrophil recovery was similar, while s-AML patients required a longer time for platelet recovery (P = 0.04). There was no difference as to eligibility for consolidation as well as for mobilization and feasibility of ASCT. S-AML had negligible impact on overall survival (OS) and disease-free survival (DFS). In the multivariate analysis the only parameter significantly related to either OS or DFS duration was adverse karyotype (P = 0.02 and 0.04, respectively). CONCLUSIONS: A diagnosis of s-AML does not represent a clinically relevant prognostic factor in elderly AML patients treated with aggressive therapy. Furthermore, s-AML patients can be mobilized and autografted with comparable results as opposed to de novo cases.


Subject(s)
Anemia, Refractory, with Excess of Blasts/complications , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Myeloid/etiology , Leukemia, Myeloid/therapy , Acute Disease , Aged , Aged, 80 and over , Antigens, CD34 , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Chromosome Aberrations , Combined Modality Therapy , Cytarabine/administration & dosage , Female , Humans , Leukemia, Myeloid/mortality , Male , Middle Aged , Prognosis , Remission Induction , Stem Cell Transplantation , Vidarabine/administration & dosage , Vidarabine/analogs & derivatives
3.
Pediatr Med Chir ; 26(1): 65-7, 2004.
Article in Italian | MEDLINE | ID: mdl-15529816

ABSTRACT

The Authors report on a 16 year-old girl, of Cambodian descent, who was admitted to the hospital for hematuria. She showed a mild microcytic, hypochromic anemia with a normal iron balance; clinical examination was normal with neither pallor nor icterus nor splenomegaly; electrophoresis of hemoglobin yielded no hemoglobin A, a sligtly increased amount of HbF and a single band with a mobility similar to that of HbA2; the patient showed no evidence of overt increased hemolysis. With the DNA technology a final diagnosis of homozygous hemoglobin E was made. Hemoglobin E is the most common Hb variant among Southeast Asian populations. The Authors discuss on the benign nature of Hb-EE disease, pointing out that the presence of a single HbE gene in combination with that for beta-thalassemia leads generally to a disorder often comparable in severity to that of homozygous beta-thalassemia. With the recent migration of a high number of people from the countries, where HbE is extremely frequent, to the Western world (including Italy), this thalassemia syndrome is now a global health problem; therefore its knowledge is an important diagnostic challenge to all the experts involved in the care of thalassemic patients.


Subject(s)
Hemoglobin E , Hemoglobinopathies/diagnosis , Adolescent , Female , Hemoglobinopathies/genetics , Homozygote , Humans
4.
Bone Marrow Transplant ; 34(7): 573-6, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15258559

ABSTRACT

There is growing interest in autologous stem cell transplantation (ASCT) for elderly patients with acute myeloid leukemia (AML). While mortality and toxicity from ASCT have been reduced, relapse rate is still high. In a prospective study, we investigated the feasibility of a new conditioning regimen consisting of high-dose idarubicin plus busulfan in AML patients aged over 60 years undergoing ASCT. A total of 14 patients (median age: 64 years) received 2 days continuous infusion of idarubicin at 20 mg/m2/day, followed by 3 days of oral busulfan (4 mg/kg/day) as conditioning. No case of transplant-related mortality occurred. The median number of days to neutrophil ( > 0.5 x 10(9)/l) and platelet ( > 20 x 10(9)/l) recovery was 11 and 12, respectively. Cardiac toxicity was absent, while 12 patients (86%) had grade 3-4 mucositis. After a median follow-up of 9 months from ASCT, nine of 14 patients are alive in continuous complete remission (CR), four have relapsed at 3, 6, 8 and 9 months, and one died in CR1 from gastric cancer. Our data demonstrate the feasibility of a conditioning regimen based on high-dose idarubicin plus busulfan in elderly AML patients. Results concerning reduction of relapse rate need confirmation in a larger series with longer follow-up.


Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Antineoplastic Agents, Alkylating/administration & dosage , Busulfan/administration & dosage , Hematopoietic Stem Cell Transplantation , Idarubicin/administration & dosage , Leukemia, Myeloid/drug therapy , Acute Disease , Administration, Oral , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Infusions, Intravenous , Leukemia, Myeloid/mortality , Male , Middle Aged , Prospective Studies , Secondary Prevention , Survival Rate , Transplantation Conditioning
SELECTION OF CITATIONS
SEARCH DETAIL
...